Harvard Bioscience, Inc. (HBIO) Earnings Call Transcripts
Harvard Bioscience, Inc.'s Latest Earnings Call - Q1 FY2026
In Q1 2026, Harvard Bioscience reported revenue of $20.8 million, in line with expectations but below the $21.8 million from Q1 2025. Adjusted gross margin improved to 59%, up 300 basis points year-over-year, while adjusted EBITDA was flat at $0.8 million. The company reaffirmed its full-year guidance, expecting 2% to 4% revenue growth and adjusted EBITDA growth of 6% to 10%. Key drivers include strong sales in new product lines and growth in China.
Reported metrics
| Metric | Value |
|---|---|
| Revenue | $20.8M (inline) |
| Adjusted Gross Margin | 59% (beat) |
| Adjusted EBITDA | $0.8M (miss) |
| Operating Loss | $1.2M (inline) |
| Adjusted EPS | -$0.33 (inline) |
Guidance from management
Management reaffirmed full-year 2026 guidance, expecting 2% to 4% revenue growth, gross margin of 58% to 60%, and adjusted EBITDA growth of 6% to 10%.
What management said
Yes. So we're definitely seeing, what I'd call, an [ unsung ] where -- or basically funds, as you know, the reconciliation bill got approved February 3. And until then, many academics were unsure if they were going to be able to spend their money. So now that the budgets were locked in, we have seen orders come through. And as you know, our sales cycle is such that if we get many of the orders would say, which come i...
Yes, Bruce, based on the [ Maanshan ] initiative, as well as we're getting some progress as well on some of our NPI products, we do expect to be able to get it flat to growth in Asia for the year.
What analysts pressed on
Analysts questioned the sustainability of growth in academia and CRO spending, noting the reliance on federal budgets and biotech financing. Concerns were also raised about the potential for continued revenue growth in Asia.
Main topics on the call
- Revenue Performance — Revenue for Q1 2026 was $20.8 million, in line with guidance but below the $21.8 million from Q1 2025. The decline was attributed to lower sales from academic institutions and distributors in APAC.
- Gross Margin Improvement — Gross margin improved to 59%, at the high end of the guidance range, driven by cost actions and higher-margin NPI revenue. Management stated, 'This puts us on a path toward consistent gross margins greater than 60%.'
- New Product Innovation (NPI) — Sales of new products like Mesh MEA, BTX, and SoHo telemetry products are expected to deliver double-digit revenue growth for the full year. These products currently represent 15% to 20% of revenue.
- Geographic Revenue Trends — Revenue in the Americas declined 9% due to lower academic and government sales, while Europe saw a 7% increase. APAC revenue fell 9%, but China grew by 3%, driven by CRO sales.
Read the full Harvard Bioscience, Inc. transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Harvard Bioscience, Inc.
Harvard Bioscience, Inc. (HBIO) is a publicly listed company in the Life Sciences Tools and Services industry, within the Health Care sector. It trades on NasdaqCM and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 28 calls on record spanning February 26, 2020 to May 12, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 28 Harvard Bioscience, Inc. earnings call transcripts on record, spanning February 26, 2020 to May 12, 2026. Based on this history, Harvard Bioscience, Inc. reports quarterly. The most recent call on file is dated May 12, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- HBIO
- Exchange
- NasdaqCM
- Country
- US
- Sector
- Health Care
- Industry
- Life Sciences Tools and Services
- Calls on record
- 28
- First call
- February 26, 2020
- Most recent
- May 12, 2026
- Reporting cadence
- quarterly